Inmedix, Inc. filed an amended Form D with the Securities and Exchange Commission on 2025-10-06.
Inmedix, Inc. filed an amended Form D notice of an exempt securities offering with the SEC on October 6, 2025. The filing reports $4.01M sold. Its industry group is Biotechnology. It names Andrew Holman, M.D. (Executive Officer, Director), Steven Daly, M.S., M.B.A. (Director), Bernie Tobin (Director) (SEC Form D/A, October 6, 2025).
In its own words: “Discover Inmedix's medical-grade HRV monitor devices for precise heart rate variability tracking.” (inmedix.com, checked November 1, 2026)
Is this your company?
Sell to companies like Inmedix, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2025-10-06 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Inmedix, Inc.
Free to see. No signup.
More on the people and the money behind Inmedix, Inc., from the filings we hold.
Biotechnology raises by companies based in Washington, filed within 90 days of this one, largest first.
Get an email when Inmedix, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Inmedix, Inc. raises, hires or launches. No email unless you switch it on.
Watch Inmedix, Inc. →Get the full cited report on Inmedix, Inc.
What the filing shows about Inmedix, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Inmedix, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives Inmedix, Inc.'s address as 17837 First Avenue South, #6, Normandy Park, WA 98148.
Saved here on this device in the meantime, so nothing is lost either way.
Full funding history for Inmedix, Inc. →
Amended on 2026-10-22: the amount sold changed from $159,980 to $4,009,945; the number of investors changed from 4 to 34. Figures on this page are from the amendment. Amended filing · Original filing
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Inmedix, Inc. is a registered filer with the SEC (CIK 1851853) and has filed since 2023-04-25. 4 filings are on record, the latest on 2026-10-22.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
Inmedix, Inc.'s Form D of 2025-10-06 names Andrew Holman, M.D., Steven Daly, M.S., M.B.A., Bernie Tobin and 3 more as its officers, directors or promoters.
Its new offerings report $905K sold across 3 offerings, as its own filings state.
A hollow marker is an amendment (Form D/A); a solid one is an original Form D. The larger marker is the filing this page is about.
Trailing twelve months. 766 filings in Biotechnology, totalled by week.
Andrew Holman, M.D. is named as Executive Officer and Director on the Form D that Inmedix, Inc. filed with the SEC on 6 October 2025, one of 6 people that filing names.
Steven Daly, M.S., M.B.A. is named as Director on the Form D that Inmedix, Inc. filed with the SEC on 6 October 2025, one of 6 people that filing names.
Bernie Tobin is named as Director on the Form D that Inmedix, Inc. filed with the SEC on 6 October 2025, one of 6 people that filing names.
Leroy Hood, M.D., Ph.D. is named as Director on the Form D that Inmedix, Inc. filed with the SEC on 6 October 2025, one of 6 people that filing names.
Kevin Tracey, M.D. is named as Director on the Form D that Inmedix, Inc. filed with the SEC on 6 October 2025, one of 6 people that filing names.
Ryan Sullivan, Ph.D. is named as Director on the Form D that Inmedix, Inc. filed with the SEC on 6 October 2025, one of 6 people that filing names.
6 people named on the filing — 1 holding an executive role and 5 as directors only.
Named as of the 2025-10-06 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Inmedix, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Inmedix, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Inmedix, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Inmedix, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Inmedix, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for Inmedix, Inc.. With no account yet, you sign up free and land on the result.
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/inmedix-inc-form-d-25000001